{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/62d20dbcffef490011c8df4b/69322142d06e17dcac6541d7?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"183. ESMO Awards - Episode 3","description":"<p>For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer.</p><p><br></p><p><strong>Studies:</strong></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=tarlatamab_with_first_line_chemoimmunotherapy_for_\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>DeLLphi-303</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=sevabertinib__bay_2927088__in_advanced_her2_mutant\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>SOHO-01</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=efficacy_of_lorlatinib_after_failure_of_a_first_li\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>ALBATROS</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=pembrolizumab_plus_chemotherapy__pem___ct__versus_\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>PAULIEN</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=primary_results_of_dream3r__durvalumab__medi4736__\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>DREAM3R</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=sacituzumab_tirumotecan__sac_tmt__vs_platinum_base\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>OptiTROP-Lung04</strong></a></p><p><br></p><p>For more episodes, resources and blog posts, visit <a href=\"https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com\" rel=\"noopener noreferrer\" target=\"_blank\">www.inquisitiveonc.com</a></p><p>Please find us on Twitter <a href=\"https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/@InquisitiveOnc!\" rel=\"noopener noreferrer\" target=\"_blank\">@InquisitiveOnc!</a></p><p>If you want us to look at a specific trial or subject, email us at <a href=\"mailto:inquisitiveonc@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\">inquisitiveonc@gmail.com</a></p><p><br></p><p>Art courtesy of Taryn Silver</p><p>Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/</p><p><br></p><p>Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.</p><p><br></p><p>Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content.</p>","author_name":"Michael Fernando and Josh Hurwitz"}